What Hormone Is in Mirena and How Does It Work?

Mirena contains levonorgestrel, a synthetic form of the hormone progesterone. The device holds a reservoir of 52 mg of levonorgestrel inside a small T-shaped plastic frame and releases it slowly into the uterus over several years. Unlike birth control pills that flood the entire body with hormones through the bloodstream, Mirena works primarily through local effects inside the uterus itself, which is why its systemic hormone levels stay relatively low. The result is a contraceptive that also reshapes how the uterine lining behaves, producing changes that extend well beyond pregnancy prevention.

Levonorgestrel and How It Gets Into Your Body

Levonorgestrel belongs to a class of synthetic hormones called progestins, which mimic the activity of your body’s own progesterone. It has been used in contraception for decades, showing up in emergency contraception pills, hormonal implants, and several types of IUDs. What makes Mirena distinctive is the delivery method: rather than traveling through your digestive system or entering through your skin, the hormone seeps directly from a cylindrical core on the IUD into the uterine cavity.

The device starts out releasing roughly 20 micrograms of levonorgestrel per day, but that rate declines steadily over time. By year eight, the release has dropped to about 7 micrograms per day, and plasma concentrations of levonorgestrel average around 100 nanograms per liter.¹ To put that in perspective, those blood levels are a fraction of what you would see with a daily birth control pill. Only about 60 percent of the total levonorgestrel reservoir is released over five years of use, which is why there is enough hormone remaining to keep the device effective well beyond that initial window.²

This slow-trickle design is the reason Mirena can stay in place for up to eight years while still preventing pregnancy. The hormone concentration is highest where it matters most, inside the uterus, and relatively low everywhere else.

How Levonorgestrel Prevents Pregnancy

Mirena does not rely on a single mechanism. It stacks several biological effects on top of each other, which is part of why its failure rate is so low. The three main ways it works are changes to cervical mucus, suppression of the uterine lining, and a foreign-body reaction inside the uterus.

The cervical mucus effect is dramatic and fast-acting. Within a short time after insertion, the levonorgestrel transforms the mucus at the entrance to the uterus into a thick, sticky barrier that sperm simply cannot get through. One study compared mucus quality in Mirena users against women without the device and found that zero percent of Mirena users showed any sperm penetration in lab tests, compared to roughly 64 percent of women without one.³ The mucus essentially becomes a wall. Even if ovulation occurs, which it sometimes does with Mirena since ovulation suppression is inconsistent at these low hormone doses, sperm are blocked from ever reaching an egg.

The second major mechanism involves the endometrium, the lining of the uterus where a fertilized egg would need to implant. Levonorgestrel causes this lining to become thin, inactive, and decidualized, a process where the tissue transforms in a way that makes it inhospitable to implantation.⁴ Studies measuring endometrial thickness in Mirena users have found strong progestin effects at every follow-up time point, with the thickest endometrium recorded in one study measuring just 3.6 mm, and most samples appearing fully suppressed.⁵ For reference, a normal endometrium during the menstrual cycle can reach 12 to 16 mm.

The third layer of protection comes from the device itself. Like all IUDs, Mirena provokes a mild foreign-body reaction inside the uterus, creating a local inflammatory environment that is unfavorable for sperm survival and egg implantation. This effect adds to the hormonal mechanisms but is secondary to them.⁶

How Effective Is It, Really?

The stacked mechanisms make Mirena one of the most effective contraceptives available. An extension trial that followed women using the 52 mg device through years six to eight found a three-year Pearl Index of 0.28, meaning fewer than three pregnancies per 1,000 women over three years. Only two pregnancies occurred in the entire extended study period, and one of those was ectopic. The cumulative failure rate over those three years was under one percent.⁷

Those numbers hold up even in the later years when levonorgestrel release rates have dropped substantially. In year eight specifically, the Pearl Index was 0.00, meaning no pregnancies were observed at all. This is consistent with the pharmacokinetic finding that even at eight years, the release rate is still comparable to what lower-dose IUD systems deliver during their approved lifespan.¹

What Mirena Does to Your Period

The endometrial thinning that makes Mirena an effective contraceptive also has a pronounced effect on menstrual bleeding, and for many people, this side effect is the main reason they choose it. Because the uterine lining stays so thin, there is simply less tissue to shed each month.

The pattern typically unfolds over the first year. In the early months, irregular spotting and breakthrough bleeding are common, a frustrating phase that causes some users to give up on the device prematurely. But by 12 months, the majority of women experience significantly lighter periods, and many reach amenorrhea, the complete absence of menstrual bleeding.⁸ The dose matters here: among women using the 52 mg device, about 11 percent were amenorrheic by 180 days after insertion, compared to 5 percent with a 19.5 mg IUD and 3 percent with a 13.5 mg version. By the end of the first year, irregular bleeding was far less common with the higher-dose device, affecting only about 6 percent of users versus 23 percent of those using the lowest-dose option.⁹

The absence of periods with Mirena is not a health concern. It reflects the suppressed endometrial lining, not a hormonal problem. The lining simply stays too thin to build up and shed. When the device is removed, the cycle returns.

Treating Heavy Menstrual Bleeding

This bleeding-reduction effect has turned Mirena into a genuine medical treatment, not just a contraceptive with a convenient side effect. In many countries, Mirena is now considered a first-line therapy for heavy menstrual bleeding, a condition that affects a significant number of people and can cause anemia, fatigue, and real disruption to daily life.¹⁰

The numbers are striking. In one clinical trial, the median blood loss among women with documented heavy bleeding dropped by over 93 percent within three cycles and nearly 98 percent by cycle six. Treatment was considered successful in about 91 percent of participants who had follow-up bleeding evaluations.¹¹ Another study found that menorrhagia was reduced in 89 percent of women within three months, and by six months all participants had resolved their heavy bleeding, with nearly 40 percent reaching amenorrhea. Hemoglobin and hematocrit levels, which had been low from chronic blood loss, recovered to normal reference ranges by the six-month mark.¹²

For people trying to avoid surgery, this matters. Research has found that the outcomes and quality-of-life improvements with Mirena are comparable to surgical options like endometrial ablation and hysterectomy, but without the operative risks, recovery time, or permanent loss of fertility.¹³

Endometrial Protection During Hormone Therapy

There is another clinical use for Mirena that gets less attention but is well supported. Postmenopausal people taking estrogen as part of hormone replacement therapy face an increased risk of endometrial hyperplasia, an overgrowth of the uterine lining that can progress to cancer. The standard approach is to take a progestin alongside estrogen to counteract this stimulation. Mirena can serve as that progestin delivery system.

Studies comparing the levonorgestrel IUD against oral or vaginal progesterone for endometrial protection have found Mirena equally effective at preventing hyperplasia.¹⁴ The advantage is that the progestin stays concentrated in the uterus rather than circulating through the whole body, which may reduce some of the systemic side effects that oral progestins can cause, like bloating, mood changes, and breast tenderness. In follow-up studies, endometrial biopsies from Mirena users on estrogen therapy consistently showed nonproliferative, suppressed tissue.⁵

How Mirena Differs From Copper IUDs

Because Mirena sits in the same device category as the copper IUD, people often wonder how the two compare mechanically. The copper IUD contains no hormones at all. Instead, it releases copper ions that create a toxic environment for sperm and trigger a stronger inflammatory reaction inside the uterus. Both device types produce a foreign-body response, but the copper IUD relies almost entirely on that reaction and the sperm-killing copper, while Mirena’s dominant effects come from levonorgestrel’s impact on mucus and the endometrium.⁶

This difference has practical implications. Copper IUDs do not thin the endometrium and can actually make periods heavier and more crampy, the opposite of what Mirena tends to do. On the other hand, copper IUDs are completely hormone-free, which matters for people who want to avoid any hormonal exposure. The choice often comes down to whether lighter periods or hormone avoidance is the higher priority.

Risks and Uncommon Complications

Mirena’s safety profile is well established, but there are a few complications worth understanding. The most commonly discussed are perforation, expulsion, and ectopic pregnancy.

Perforation, where the device pushes through the uterine wall during or after insertion, is uncommon. The overall rate sits around one in 1,000 insertions.¹⁵ A large comparative study found that levonorgestrel IUDs had a slightly higher perforation rate than copper IUDs, with the one-year cumulative incidence at about 0.22 percent for hormonal devices versus 0.16 percent for copper, though both numbers are low. Expulsion rates, where the device partially or fully slips out of the uterus, were similar between the two types, with roughly 2.3 percent of users in each group experiencing expulsion within the first year.¹⁶ Some research has found an association between breastfeeding at the time of insertion and perforation risk, though causation has not been firmly established.

Ectopic pregnancy, where a fertilized egg implants outside the uterus, is rare with any IUD because IUDs are so good at preventing pregnancy in the first place. But when pregnancies do occur with an IUD in place, a disproportionate share are ectopic. A recent large study comparing ectopic pregnancy rates across IUD types found that the 52 mg levonorgestrel IUD actually had a lower ectopic pregnancy rate than the copper IUD, with a hazard ratio of 0.62. Interestingly, lower-dose levonorgestrel IUDs had higher rates than copper, suggesting that the degree of endometrial suppression matters.¹⁷

Does Mirena Affect Your Metabolism?

A reasonable concern with any hormonal method is whether the hormone is altering things like cholesterol, blood sugar, or blood pressure. Because Mirena’s levonorgestrel stays mostly local, the metabolic footprint is small. Randomized studies comparing Mirena users to copper IUD users have found no meaningful adverse changes in triglycerides, LDL cholesterol, liver enzymes, or cholesterol ratios over a year of follow-up.¹⁸ One study did note a transient dip in HDL cholesterol at six months, but levels returned to baseline by 12 months. Blood pressure, fasting glucose, and liver function remained stable.¹⁹

This is reassuring and consistent with what you would expect from a device that produces systemic hormone levels well below those of oral contraceptives. It does not mean the device has zero systemic effects. Some users do report side effects that suggest hormonal influence, such as acne, breast tenderness, headaches, and mood changes. These are plausible given that some levonorgestrel does enter the bloodstream, just at much lower levels than with pills or implants.

Fertility After Removal

One of the persistent anxieties about IUDs is whether they impair fertility after removal. The evidence here is clear and reassuring. In studies following women who had their IUDs removed specifically to try to conceive, over 94 percent became pregnant, with the majority conceiving within the first three months.²⁰ The endometrial suppression that levonorgestrel causes reverses quickly once the device is gone. Biopsies taken after a washout period show the lining returning to a normal, atrophic baseline before cycling resumes.⁵

There is one unusual edge case worth mentioning. In rare instances where a Mirena device migrates outside the uterus (a complication of perforation), the levonorgestrel can produce higher-than-intended systemic levels and potentially suppress ovulation more completely than normal. A case report documented a woman whose displaced Mirena was found outside her uterus; after laparoscopic removal, she conceived within a month.²¹ The takeaway is that even in worst-case displacement scenarios, the contraceptive effect is reversible once the device is out.

Why There Are Multiple Levonorgestrel IUD Sizes

Mirena is the original and highest-dose levonorgestrel IUD, but it now shares the market with smaller devices containing 19.5 mg and 13.5 mg of levonorgestrel. These lower-dose IUDs were designed for people who want a smaller frame, which can make insertion easier, particularly for those who have not had children. The trade-off is that the lower hormone load produces less endometrial suppression, which means less period reduction and, in some situations, slightly different risk profiles.

By year five, the 19.5 mg device releases levonorgestrel at a rate similar to what the 52 mg Mirena delivers at year eight, and its plasma concentrations are in the same ballpark.¹ The 13.5 mg device, with the least levonorgestrel, drops to its lowest release rate by year three. From a practical standpoint, this means lower-dose IUDs are approved for shorter durations: five years for the 19.5 mg version and three years for the 13.5 mg version, versus up to eight years for Mirena.

The ectopic pregnancy data hint at a real clinical consequence of these dose differences. The 52 mg device was associated with a lower ectopic pregnancy risk than the copper IUD, while the 13.5 mg device had a meaningfully higher risk.¹⁷ The likely explanation is that the higher levonorgestrel dose more thoroughly suppresses the endometrium and tubal activity, reducing the chance that a fertilized egg could implant anywhere at all. With the smallest device delivering less hormone, those protective effects are not as strong.